SCHEMBL6436598

SCHEMBL6436598

[CH2]C(CO)OCP

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4311855 0.73
SCHEMBL6436203 0.71
SCHEMBL6437610 0.71
SCHEMBL1140792 0.69
SCHEMBL10523283 0.67
SCHEMBL11433455 0.67
SCHEMBL6437728 0.65
SCHEMBL10520258 0.64
SCHEMBL910847 0.63
SCHEMBL1079368 0.62 ALDH1A1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE36187-E HERPES SIMPLEX VIRUS; HUMAN CYTOMEGALOVIRUS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1999-04-06 US claimed
US-4968686-A DECREASED CYTOTOXICITY; CYTOMEGALO AND HERPEX SIMPLEX VIRUSES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1990-11-06 US claimed
EP-1097720-B1 Antiviral agent in combination with radiation therapy for use in treatment of cancer ROUSSY INST GUSTAVE (FR) 2005-10-12 EP disclosed
US-20040192637-A1 Antiviral agent for use in treatment of cancer INSTITUT GUSTAVE ROUSSY (FR) 2004-09-30 US disclosed
US-6723712-B2 Antiviral agent for use in treatment of cancer INSTITUT GUSTAVE ROUSSY (FR) 2004-04-20 US disclosed
EP-1246623-A4 COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF OSI PHARM INC (US) 2003-05-14 EP disclosed
US-20020193339-A1 Antiviral agent for use in treatment of cancer INSTITUT GUSTAVE ROUSSY (FR) 2002-12-19 US disclosed
EP-1246623-A1 COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF OSI Pharmaceuticals, Inc. (US) 2002-10-09 EP disclosed
EP-1237576-A1 ANTIVIRAL AGENT FOR USE IN TREATMENT OF CANCER INSTITUT GUSTAVE ROUSSY (FR) 2002-09-11 EP disclosed
WO-2001039777-A1 COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF OSI PHARMACEUTICALS, INC. (US) 2001-06-07 WO disclosed
WO-2001032215-A1 ANTIVIRAL AGENT FOR USE IN TREATMENT OF CANCER INSTITUT GUSTAVE ROUSSY (FR) 2001-05-10 WO disclosed
US-5386030-A Chemical intermediates INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCE OF THE CZECH REPUBLIC (CZ) 1995-01-31 US disclosed
EP-0574386-A1 NOVEL PROCESS FOR THE PREPARATION OF NUCLEOTIDES INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 1993-12-22 EP disclosed
EP-0574386-A4 NOVEL PROCESS FOR THE PREPARATION OF NUCLEOTIDES. BRISTOL MYERS SQUIBB CO (US) 1993-10-27 EP disclosed
US-5208221-A Nucleotides and intermediates for herpes virus or leukemia virus BRISTOL-MYERS SQUIBB COMPANY (US) 1993-05-04 US disclosed
EP-0494370-A1 Antiviral (phosphonomethoxy)methoxy purine/pyrimidine derivatives INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) 1992-07-15 EP disclosed
WO-1992002511-A1 NOVEL PROCESS FOR THE PREPARATION OF NUCLEOTIDES BRISTOL-MYERS SQUIBB COMPANY (US) 1992-02-20 WO disclosed
EP-0454427-A1 Antiretroviral bases Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (CZ) 1991-10-30 EP disclosed
US-4968686-A DECREASED CYTOTOXICITY; CYTOMEGALO AND HERPEX SIMPLEX VIRUSES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1990-11-06 US disclosed
US-4927830-A HERPES, CYTOMEGALO VIRUS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1990-05-22 US disclosed